MRK: Sac-TMT Gets FDA Breakthrough Therapy Designation For EGFR-mutated Advanced Or Metastatic NSCLC
Merck & Co., Inc. (MRK) announced Tuesday that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to ...
News Medical2d
How Dysregulated Cell Signaling Causes Disease
Dysregulated cell signaling underlies various diseases, emphasizing the importance of understanding these pathways for ...
Cure Today23h
FDA Grants Breakthrough Therapy Designation to Sac-TMT for Some with NSCLC
The FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for patients with advanced or metastatic ...
The Brighterside of News on MSN3d
Cutting-edge discovery looks to transform type 1 diabetes, cancer and autoimmune disease care
Regenerative medicine has the potential to reshape how we treat diseases, offering new hope for patients requiring cell, ...
In the US, young and middle-aged women are being diagnosed with lung cancer at higher rates than men
Susan Wojcicki, the late CEO of YouTube, had a message for the world just weeks before she passed away in August: “Lung ...
Janux Therapeutics (NASDAQ:JANX) Given Outperform Rating at William Blair
William Blair restated their outperform rating on shares of Janux Therapeutics (NASDAQ:JANX – Free Report) in a research note ...
Cure Today13d
Radiotherapy and EGFR-TKIs May Improve Treatment Outcomes in Lung Cancer
CURE® spoke with a lung cancer treatment expert about study findings showing survival benefits with the addition of ...
Merck: FDA grants Breakthrough Therapy designation to sacituzumab tirumotecan
Merck (MRK) announced that the U.S. FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for the treatment of patients with advanced or metastatic nonsquamous non-small cell ...